DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR TEGSEDI

« Back to Dashboard

All Clinical Trials for TEGSEDI

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT04136184	NEURO-TTRansform: A Study to Evaluate the Efficacy and Safety of AKCEA-TTR-LRx in Participants With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy	Not yet recruiting	Akcea Therapeutics	Phase 3	2019-10-01	To evaluate the efficacy and safety of AKCEA-TTR-LRx after administration for 65 weeks to patients with hereditary transthyretin-mediated amyloid polyneuropathy (hATTR-PN), as compared to the NEURO-TTR trial (NCT01737398).
NCT04136184	NEURO-TTRansform: A Study to Evaluate the Efficacy and Safety of AKCEA-TTR-LRx in Participants With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy	Not yet recruiting	Ionis Pharmaceuticals, Inc.	Phase 3	2019-10-01	To evaluate the efficacy and safety of AKCEA-TTR-LRx after administration for 65 weeks to patients with hereditary transthyretin-mediated amyloid polyneuropathy (hATTR-PN), as compared to the NEURO-TTR trial (NCT01737398).

Clinical Trial Conditions for TEGSEDI

Condition Name

Condition Name for TEGSEDI
Intervention	Trials
Hereditary Transthyretin-Mediated Amyloid Polyneuropathy	1

Condition MeSH

Condition MeSH for TEGSEDI
Intervention	Trials
Polyneuropathies	1
Amyloidosis	1
Amyloid Neuropathies	1

Clinical Trial Progress for TEGSEDI

Clinical Trial Phase

Clinical Trial Phase for TEGSEDI
Clinical Trial Phase	Trials
Phase 3	1

Clinical Trial Status

Clinical Trial Status for TEGSEDI
Clinical Trial Phase	Trials
Not yet recruiting	1

Clinical Trial Sponsors for TEGSEDI

Sponsor Name

Sponsor Name for TEGSEDI
Sponsor	Trials
Ionis Pharmaceuticals, Inc.	1
Akcea Therapeutics	1

Sponsor Type

Sponsor Type for TEGSEDI
Sponsor	Trials
Industry	2